Genetic Polymorphisms of ATP-Binding Cassette Transporters ABCB1 and ABCC2 and their Impact on Drug Disposition

被引:52
作者
Haufroid, Vincent [1 ,2 ]
机构
[1] Hop St Luc, Analyt Chem Lab, B-1200 Brussels, Belgium
[2] Catholic Univ Louvain, Louvain Ctr Toxicol & Appl Pharmacol LTAP, B-1200 Brussels, Belgium
关键词
Pharmacogenomics; ABCB1; ABCC2; intracellular concentrations; genotype; polymorphism; mdr1; mrp2; SINGLE-NUCLEOTIDE POLYMORPHISMS; MULTIDRUG-RESISTANCE GENE; TACROLIMUS DOSE REQUIREMENTS; MDR1 C3435T POLYMORPHISM; STEADY-STATE PHARMACOKINETICS; INTESTINAL P-GLYCOPROTEIN; LUNG-TRANSPLANT PATIENTS; RENAL-TRANSPLANT; TROUGH CONCENTRATIONS; MYCOPHENOLIC-ACID;
D O I
10.2174/138945011795378487
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The ATP-binding cassette (ABC) transporter superfamily comprises membrane proteins that translocate a variety of substrates across extra- and intra-cellular membranes, and act as efflux proteins. ABC transporters are characterised by the presence of genetic polymorphisms mainly represented by single nucleotide polymorphisms (SNPs), some of which having an impact on their activity. Besides physiological substances, drugs are also substrates of some ABC transporters, mainly ABCB1, ABCC1, ABCC2, ABCC3 and ABCG2. Identifying the impact of these polymorphisms on the pharmacokinetics (PK) of these drugs may have important clinical implications, certainly for those characterised by a narrow therapeutic index and significant inter- and intra-patient PK variability. This review focuses specifically on ABCB1 and ABCC2 and critically analyses important publications dealing with the influence of ABCB1 and/or ABCC2 polymorphisms on drug disposition in humans. For different reasons discussed in this paper, the effect of ABCB1 and/or ABCC2 polymorphisms on drug concentrations in blood is not always easy to interpret and to correlate with pharmacological effects. In contrast, intracellular or target tissue drug concentrations appear more directly influenced by these polymorphisms, as illustrated with intralymphocyte concentrations for immunosupressants and antiretrovirals or with cerebrospinal fluid (CSF) concentrations for antiepileptics and antidepressants. Further research on intracellular and/or target tissue drug concentrations are still needed to better characterise the PK-PG (pharmacogenetics) relationship involving ABC transporters.
引用
收藏
页码:631 / 646
页数:16
相关论文
共 153 条
[51]   The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? [J].
Hesselink, DA ;
van Gelder, T ;
van Schaik, RHN .
PHARMACOGENOMICS, 2005, 6 (04) :323-337
[52]   Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients [J].
Hirt, Deborah ;
Mentre, France ;
Tran, Agnes ;
Rey, Elisabeth ;
Auleley, Solange ;
Salmon, Dominique ;
Duval, Xavier ;
Treluyer, Jean-Marc .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (04) :548-557
[53]   Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants [J].
Ho, Richard H. ;
Choi, Leena ;
Lee, Wooin ;
Mayo, Gail ;
Schwarz, Ute I. ;
Tirona, Rommel G. ;
Bailey, David G. ;
Stein, C. Michael ;
Kim, Richard B. .
PHARMACOGENETICS AND GENOMICS, 2007, 17 (08) :647-656
[54]   Functional polymorphisms of the human multidrug-resistance gene:: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J].
Hoffmeyer, S ;
Burk, O ;
von Richter, O ;
Arnold, HP ;
Brockmöller, J ;
Johne, A ;
Cascorbi, I ;
Gerloff, T ;
Roots, I ;
Eichelbaum, M ;
Brinkmann, U .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3473-3478
[55]   Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation [J].
Hu, Yong-Fang ;
Qiu, Wen ;
Liu, Zhao-Qian ;
Zhu, Li-Jun ;
Liu, Zhong-Qi ;
Tu, Jiang-Hua ;
Wang, Dan ;
Li, Zhi ;
He, Jun ;
Zhong, Gan-Ping ;
Zhou, Gan ;
Zhou, Hong-Hao .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2006, 33 (11) :1093-1098
[56]   Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics [J].
Innocenti, Federico ;
Kroetz, Deanna L. ;
Schuetz, Erin ;
Dolan, M. Eileen ;
Ramirez, Jacqueline ;
Relling, Mary ;
Chen, Peixian ;
Das, Soma ;
Rosner, Gary L. ;
Ratain, Mark J. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2604-2614
[57]   Meta-Analysis of the Effect of MDR1 C3435T Polymorphism on Cyclosporine Pharmacokinetics [J].
Jiang, Zhi-Ping ;
Wang, Yi-Ren ;
Xu, Ping ;
Liu, Rong-Rong ;
Zhao, Xie-Lan ;
Chen, Fang-Ping .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2008, 103 (05) :433-444
[58]   Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers [J].
Jiko, Mari ;
Yano, Ikuko ;
Sato, Eriko ;
Takahashi, Kazushige ;
Motohashi, Hideyuki ;
Masuda, Satohiro ;
Okuda, Masahiro ;
Ito, Noriyuki ;
Nakamura, Eijiro ;
Segawa, Takehiko ;
Kamoto, Toshiyuki ;
Ogawa, Osamu ;
Inui, Ken-Ichi .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2007, 12 (04) :284-290
[59]   Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene [J].
Johne, A ;
Köpke, K ;
Gerloff, T ;
Mai, I ;
Rietbrock, S ;
Meisel, C ;
Hoffmeyer, S ;
Kerb, R ;
Fromm, MF ;
Brinkmann, U ;
Eichelbaum, M ;
Brockmöller, J ;
Cascorbi, I ;
Roots, I .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (05) :584-594
[60]  
Kerb R., 2001, Pharmacogenomics Journal, V1, P204